Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome.

CONCLUSION: In this study, similar 12-month event rates were observed for both BRS types after implantation for the treatment of ACS. PMID: 31209520 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research